Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Recruiting

Phase 1

RMC-6236Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Sponsor:

Revolution Medicines, Inc.

Code:

NCT05379985

Conditions

Non-small Cell Lung Cancer (NSCLC)

Colorectal Cancer (CRC)

Pancreatic Ductal Adenocarcinoma (PDAC)

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

RMC-6236

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-14. This information was provided to ClinicalTrials.gov by Revolution Medicines, Inc. on 2024-11-14.